Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 12/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 11/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 9/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.55 |
| ▸ | PTGFR | P43088 | 3/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.54 |
| ▸ | PTGIR | P43119 | 2/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557047 | 1.00 | PTGER3 (0.61) | PTGER3PTGER2PTGER4CA1CA2 | |
| SCHEMBL28598089 | 1.00 | PTGER3 (0.61) | PTGER3PTGER2PTGER4CA1CA2 | |
| SCHEMBL10350742 | 0.86 | PTGER3 (0.58) | PTGER3PTGER2PTGER4CA1CA2 | |
| SCHEMBL28331101 | 0.84 | MAPT (0.54) | NFKB1MAPT | |
| SCHEMBL6274122 | 0.83 | PTGER3 (0.63) | PTGER3PTGER2PTGER4CA1CA2 | |
| SCHEMBL6274118 | 0.83 | PTGER3 (0.63) | PTGER3PTGER2PTGER4CA1CA2 | |
| SCHEMBL3214322 | 0.83 | PTGER3 (0.63) | PTGER3PTGER2PTGER4CA1CA2 | |
| SCHEMBL309761 | 0.83 | PTGER3 (0.63) | PTGER3PTGER2PTGER4CA1CA2 | |
| SCHEMBL1150939 | 0.83 | PTGER3 (0.63) | PTGER3PTGER2PTGER4CA1CA2 | |
| SCHEMBL8105303 | 0.81 | PTGER3 (0.61) | PTGER3PTGER2PTGER4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842825-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7700632-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | CHU CHANG AN | 2008-10-16 | — | — | US | disclosed |
| US-20080108662-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | CHU CHANG A | 2008-05-08 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20010031766-A1 | Prostaglandin receptor ligands | MERCK FROSST CANADA & CO. | 2001-10-18 | — | — | US | disclosed |
| EP-1119542-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | Merck Frosst Canada & Co. (CA) | 2001-08-01 | — | — | EP | disclosed |
| US-6242493-B1 | PROSTAGLANDIN INHIBITORS; ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-06-05 | — | — | US | disclosed |
| EP-1000024-A1 | MERCAPTOACYLAMINO ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000020371-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | MERCK FROSST CANADA & CO. (CA) | 2000-04-13 | — | — | WO | disclosed |
| WO-1999006365-A1 | MERCAPTOACYLAMINO ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108662-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | GYS2, PYGL, GYS1 | PTGER3 1136/4885PTGER2 1847/4885PTGER4 1354/4885 |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | GYS2, PYGL, GYS1 | PTGER3 1136/4885PTGER2 1847/4885PTGER4 1354/4885 |
| US-20010031766-A1 | Prostaglandin receptor ligands | PTGER1, PTGER2, PTGFR | PTGER3 9/4885PTGER2 2/4885PTGER4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.